title: [Tolvaptan and autosomal dominant polycystic kidney disease in the adult: let's give time to the "TEMPO" trial (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes)].
authors.forename: Antonio
authors.initials: A
authors.lastname: Lacquaniti
mesh_terms: D000328:Adult; D065092:Antidiuretic Hormone Receptor Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D001552:Benzazepines / Q000009:adverse effects / Q000627:therapeutic use*; D015415:Biomarkers / Q000378:metabolism; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000378:metabolism; D018450:Disease Progression; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D016891:Polycystic Kidney, Autosomal Dominant / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D012307:Risk Factors; D012720:Severity of Illness Index; D013997:Time Factors; D000077602:Tolvaptan; D014511:Uremia / Q000209:etiology / Q000517:prevention & control
chemical_list: D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines; D015415:Biomarkers; D000077602:Tolvaptan; D003404:Creatinine